Luigi Naldi

Luigi Naldi

Bergamo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 313 publications

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 11, 2026

The worldwide burden of skin diseases: Lessons from the Global Burden of Disease data.

The worldwide burden of skin diseases: Lessons from the Global Burden of Disease data.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 16, 2026

Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study.

Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study.

Journal: Psoriasis (Auckland, N.Z.)

Published: January 05, 2026

Human expertise or artificial intelligence? A prospective study on nail disorder diagnosis.

Human expertise or artificial intelligence? A prospective study on nail disorder diagnosis.

Journal: NPJ digital medicine

Published: December 24, 2025

Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis).

Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis).

Journal: Acta dermato-venereologica

Published: November 16, 2025

Association of comorbidities and drug intake with generalized chronic pruritus: A multicenter case-control study in Switzerland and Italy.

Association of comorbidities and drug intake with generalized chronic pruritus: A multicenter case-control study in Switzerland and Italy.

Journal: JAAD international

Published: October 13, 2025

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.

Journal: Acta dermato-venereologica

Published: October 08, 2025

Title Not Found

Title Not Found

Journal: Recenti progressi in medicina

Published: October 02, 2025

Early Childhood Stress and the Risk of Psoriasis: What Next?

Early Childhood Stress and the Risk of Psoriasis: What Next?

Journal: The Journal of investigative dermatology

Published: September 07, 2025

Practical recommendations for seborrheic dermatitis management: An expert consensus.

Practical recommendations for seborrheic dermatitis management: An expert consensus.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: August 13, 2025

Association Between Contact Allergy to Epoxy Resin and Fragrance Mix I in the General Population: EDEN Fragrance Study Group.

Association Between Contact Allergy to Epoxy Resin and Fragrance Mix I in the General Population: EDEN Fragrance Study Group.

Journal: Contact dermatitis

Published: July 03, 2025

Bridging the gap: Assessing safety beyond clinical trials in psoriasis.

Bridging the gap: Assessing safety beyond clinical trials in psoriasis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 25, 2025

Showing 1-12 of 313

Last Updated: 09/26/2026